The actual incidence of DIIP was 1.0% of total patients in this study, which was similar to the incidence of DIIP by humanized biologics targeting TNF-alpha (0.5%) in Japanese postmarketing surveillance for Rheumatoid Arthritis [23]. The gene discussed is TNF; the disease is rheumatoid arthritis.